Caspofungin

Generic Name: Caspofungin

Brand Names: Cancidas, Cancidas (previously Caspofungin MSD)

Drug Type: Small Molecule

Chemical Formula: C_₅₂H_₈₈N_₁₀O_₁₅

CAS Number: 162808-62-0

Unique Ingredient Identifier: F0XDI6ZL63

Background: Caspofungin (brand name Cancidas worldwide) is an antifungal drug and the first member of a new drug class called the echinocandins, as coined by Merck & Co., Inc. It is typically administered intravenously. It shows activity against infections with Aspergillus and Candida, and works by inhibiting β(1,3)-D-Glucan of the fungal cell wall.

Indication: For the treatment of esophageal candidiasis and invasive aspergillosis in patients who are refractory to or intolerant of other therapies.

Associated Conditions: Abscess, Intra-Abdominal, Candidemia, Esophageal Candidiasis, Fungal Infections, Invasive Aspergillosis, Oropharyngeal Candidiasis, Peritonitis, Pleural space infections

Clinical Trials

A Trial of Intravenous HRS9432 in the Treatment of Subjects With Candidemia and/or Invasive Candidiasis

Phase 2

Recruiting

Conditions: Patients With Candidemia and/or Invasive Candidiasis

Interventions: Drug: HRS9432
Drug: Caspofungin Acetate for Injection

First Posted Date: 2024-01-08

Last Posted Date: 2024-11-18

Lead Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.

Target Recruit Count: 40

Registration Number: NCT06194201

Locations: 🇨🇳
The First Affiliated Hospital Of University Of South China, Hengyang, Hunan, China

Effect of Azole/Echinocandin Use on Tacrolimus Pharmacokinetics

Completed

Conditions: Kidney Transplant Patients

Interventions: Drug: Combined with voriconazole
Drug: Combined with caspofungin
Drug: Tacrolimus-alone treatment

First Posted Date: 2023-09-21

Last Posted Date: 2023-09-28

Lead Sponsor: LI YAN

Target Recruit Count: 507

Registration Number: NCT06044558

Locations: 🇨🇳
Shandong Provincial Qianfoshan Hospital, Jinan, Shandong, China

A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis.

Phase 3

Recruiting

Conditions: Candidemia
Candidiasis, Invasive

Interventions: Drug: Fosmanogepix
Drug: Caspofungin
Drug: Placebo
Drug: Fluconazole

First Posted Date: 2022-06-16

Last Posted Date: 2025-05-16

Lead Sponsor: Basilea Pharmaceutica

Target Recruit Count: 450

Registration Number: NCT05421858

Locations: 🇮🇹
Hospital San Raffaele, IRCCS, Milan, Italy
🇮🇹
Polyclinic San Matteo, IRCCS, Pavia, Italy
🇮🇹
University Hospital of Pisa, Pisa, Italy

and more 67 locations

PK/PD of Caspofungin in Children Severe Infection

Recruiting

Conditions: Infection, Fungal
Pharmacokinetics

Interventions: Drug: Caspofungin

First Posted Date: 2021-07-14

Last Posted Date: 2025-02-20

Lead Sponsor: Children's Hospital of Fudan University

Target Recruit Count: 60

Registration Number: NCT04961593

Locations: 🇨🇳
Children's Hospital of Fudan University, Shanghai, Shanghai, China

To Evaluate the Efficacy and Safety of Micafungin in Preventing Invasive Mycosis After Liver Transplantation

Phase 4

Not yet recruiting

Conditions: Liver Transplantation

Interventions: Drug: Micafungin Sodium 50 MG Injection
Drug: Caspofungin Acetate

First Posted Date: 2021-01-28

Last Posted Date: 2022-08-16

Lead Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Target Recruit Count: 200

Registration Number: NCT04728971

Trimethoprim/Sulfamethoxazole Combined With Caspofungin as First-line Therapy in PCP

Phase 4

Conditions: Pneumocystis Pneumonia

Interventions: Drug: caspofungin
Drug: TMP/SMZ(trimethoprim/sulfisoxazole)
Drug: Methylprednisolone

First Posted Date: 2019-06-07

Last Posted Date: 2019-09-12

Lead Sponsor: Bin Du

Target Recruit Count: 122

Registration Number: NCT03978559

Locations: 🇨🇳
MICU of Peking Union Medical College, Beijing, China

Empiric Therapy of Patients With Persistent Fever and Agranulocytosis Using Caspofungin

Phase 2

Completed

Conditions: Fungal Infection

Interventions: Drug: Caspofungin

First Posted Date: 2019-02-28

Last Posted Date: 2021-07-07

Lead Sponsor: Cttq

Target Recruit Count: 32

Registration Number: NCT03857399

Locations: 🇨🇳
Jiangsu Province Hospital, Nanjing, Jiangsu, China
🇨🇳
Tongji Hospital of Shanghai, Shanghai, Shanghai, China
🇨🇳
Affiliated Concord Hospital of Fujian Medical University, Fuzhou, Fujian, China

and more 3 locations

Pharmacokinetics/Pharmacodynamics (PK/PD) of Caspofungin in Intensive Care Unit (ICU) Patients. An Open Observational Study for Antifungal Treatment's Optimization

Completed

Conditions: Critical Illness
Infection

Interventions: Drug: Caspofungin

First Posted Date: 2019-01-10

Last Posted Date: 2019-01-17

Lead Sponsor: Careggi Hospital

Target Recruit Count: 20

Registration Number: NCT03798600

Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis

Phase 3

Completed

Conditions: Candidemia
Fungal Infection
Invasive Candidiases
Mycoses

Interventions: Drug: Rezafungin for Injection
Drug: Caspofungin
Drug: oral placebo
Drug: Fluconazole
Drug: intravenous placebo

First Posted Date: 2018-09-12

Last Posted Date: 2023-01-06

Lead Sponsor: Cidara Therapeutics Inc.

Target Recruit Count: 199

Registration Number: NCT03667690

Locations: 🇮🇱
Chaim Sheba Medical Center, Tel Hashomer, Israel
🇪🇸
Hospital Clinic of Barcelona, Barcelona, Spain
🇮🇹
University Polyclinic Foundation Agostino Gemelli - IRCCS, Rome, Italy

and more 129 locations

Study Comparing Caspofungin to Placebo for the Treatment of ICU Intra-abdominal Candidiasis

Phase 3

Recruiting

Conditions: ICU Yeast Intra-abdominal Infection

Interventions: Other: placebo
Drug: caspofungin antifungal therapy

First Posted Date: 2018-07-09

Last Posted Date: 2024-07-10

Lead Sponsor: Centre Hospitalier Universitaire, Amiens

Target Recruit Count: 448

Registration Number: NCT03580733

Locations: 🇫🇷
CHU Amiens, Amiens, France

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy